The Showdown Over Puberty Blockers for Children

Family First staff writers

The debate over puberty blockers is no longer theoretical. It is no longer hypothetical and speculative. And it is no longer confined to activist slogans.

The landmark UK case Bell v Tavistock exposed serious failures in paediatric gender medicine. These failures are now driving policy change across the UK, Europe, and New Zealand. As New Zealand prepares for a High Court hearing brought by the Professional Association for Transgender Health Aotearoa (PATHA) this week*, it is vital to understand what is truly at stake.

Keira Bell was referred to the UK’s Tavistock gender clinic at age 15. At 16, she was prescribed puberty blockers. By 17, she was given testosterone. At 20, despite later saying she had serious doubts about transitioning, she underwent a bilateral mastectomy (the irreversible removal of both breasts).

Bell later described a traumatic childhood marked by depression, anxiety, social isolation, gender non‑conformity and deep body hatred. She said that online resources and peer narratives convinced her that her pain could be explained – and solved – by the idea that she was “born in the wrong body”.

When Bell later attempted to detransition, she discovered that many of the physical changes were permanent. She concluded she had never fully understood what was being done to her as a child. That realisation led her to challenge the Tavistock Clinic in court.

In Bell v Tavistock, three senior judges delivered findings of extraordinary significance.

The court found only limited evidence for the effectiveness, purpose, or long‑term impacts of puberty blockers for gender dysphoria and stated it was correct to regard the treatment as experimental.

The judges sharply criticised the clinic for failing to analyse its own data, including:

• the dramatic rise in referrals, especially among adolescent girls
• the near‑universal progression from puberty blockers to cross‑sex hormones
• the high rates of autism and mental‑health comorbidities among patients

Crucially, the court concluded that it was highly unlikely that children under 13 could give valid consent to such treatment, and even for 14‑ and 15‑year‑olds, the validity of consent was highly questionable. The interventions were described as “highly unusual” because they involve inducing radical physical changes in a condition that does not entail any direct physical disease.

Although the Tavistock Clinic later succeeded on appeal on narrow legal grounds, the factual findings were never overturned. Within days of the judgment, the NHS suspended referrals for individuals under 16. Those findings fed directly into the independent Cass Review, led by Hilary Cass, former president of the Royal College of Paediatrics and Child Health.

The Cass Review concluded that the UK’s National Health Service (NHS) had let vulnerable children down by straying from evidence‑based medicine under ideological pressure. The review found no reliable evidence that puberty blockers “buy time to think”, improve mental wellbeing, or deliver long‑term benefits. As a result, the Tavistock service was dismantled, and NHS England effectively ceased prescribing puberty blockers for minors.

The UK is not alone. Following their own systematic evidence reviews, other nations, including Sweden, Finland, Norway and Denmark, have sharply restricted puberty blockers for minors, limiting their use to exceptional cases or controlled research environments. These changes reflect medicine returning to first principles: do no harm, especially to children

This is not culture‑war politics. It is medicine correcting course.

Why this matters for New Zealand

On November 19, 2025, New Zealand’s Health Minister Simeon Brown announced regulations under the Medicines Act 1981 that ban new prescriptions of puberty blockers for those under 18 suffering from gender dysphoria or incongruence. Patients already receiving treatment can continue with proper consent. This move came after a Ministry of Health review that supported the Cass findings, and it was implemented by an elected government with a defined policy mandate.

As expected, activist groups challenged it. PATHA claims the government failed to properly consult, used the wrong decision‑maker, acted for an improper political purpose and breached the New Zealand Bill of Rights Act. It is key to note that PATHA is not challenging the international evidence base directly but rather the process by which the regulations were made.

In December 2025, the High Court granted interim relief, halting enforcement. The Court of Appeal upheld this in February 2026. The regulations remain in force but are currently suspended, with a full hearing scheduled for this week

In her recent NZ Herald opinion piece, Lady Deborah Chambers KC rightly warned that PATHA’s case raises deeper issues about the judicialisation of politics. Parliament grants broad regulation-making powers, but courts must not overreach into policy disagreements over evidence.

She highlights that this case underscores why the boundary between judicial oversight and democratic decision-making must be carefully guarded. That democracy functions best when elected politicians are permitted to make the difficult calls they were elected to make, and when courts reserve intervention for genuine excesses of power rather than disagreements over evidence or ideology. Judicial review remains essential. But it must not become a veto power for the unelected.

This PATHA case demonstrates how well-funded interest groups can manipulate the judicial process to delay or undermine democratic decisions, even those based on international evidence and intended to protect children. While courts tend to prioritise process over policy judgment, a precedent is forming. Excessive judicial intervention in controversial social issues risks leaving decisions by elected officials indefinitely unresolved.

The Bell v Tavistock saga demonstrated the human cost of silencing dissent and letting gender ideology run unchecked. The PATHA case will test whether New Zealand has truly learned from those mistakes or whether ideology will override caution and protect children from harm.

Children deserve care, caution and protection, not irreversible medical experimentation driven by ideology. We will closely monitor this case and continue to advocate for policies and laws that safeguard our most precious treasures – our children, our future.

This article was originally published by Family First New Zealand.

*Editor’s note: